SR-A + epratuzumab

SR-A + epratuzumab is a chemo-immunotherapy regimen investigated in the **IntReALL SR 2010** Phase III clinical trial for pediatric patients with standard-risk (SR) first relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The regimen combines a multi-agent chemotherapy backbone (SR-A), which is based on the German **ALL-REZ BFM 2002 Protocol** (specifically the Protocol II IDA arm), with **epratuzumab**, a humanized IgG1 monoclonal antibody. Epratuzumab targets the **CD22** glycoprotein, a cell surface antigen expressed on mature B-cells and malignant B-cell precursors. The SR-A chemotherapy component typically includes agents such as dexamethasone, vincristine, idarubicin, cytarabine, etoposide, and L-asparaginase. The addition of epratuzumab was intended to enhance the efficacy of standard chemotherapy through targeted B-cell modulation and depletion, although Phase III results indicated that the combination did not significantly improve event-free survival compared to chemotherapy alone.

Other names

epratuzumab plus SR-A chemotherapyIntReALL SR 2010 SR-A + epratuzumab